Effectiveness of OsteoKing in the Treatment of Lumbar Disc Herniation: A Randomized, Double‑Blind, Double‑Dummy, Positive‑Controlled, Multicenter Clinical Trial

医学 可视模拟标度 Oswestry残疾指数 腰椎 临床试验 临床终点 外科 腰痛 不利影响 随机对照试验 最小临床重要差异 多中心研究 背痛 多中心试验 重复措施设计 麻醉 腰椎 随机化 置信区间 物理疗法 腰椎间盘突出症 安慰剂 入射(几何) 临床疗效
作者
Zhuoyun Wu,Shiyu Dong,马宏庆,Y Y,Kuayue Zhang,Xuehui Wang,Hao Wang,Shuangqing Du,Wenjie Wu,Tao Fan,Jian Wei,Wenge Wang,Yue Han,Chao Ma,Fuhong Cheng,Yuan Pang,Rongxin Sun,Ziqiang Zhu,Linlin Chen,Wei Fang
出处
期刊:Journal of Evidence-based Medicine [Wiley]
卷期号:19 (2): e70140-e70140
标识
DOI:10.1111/jebm.70140
摘要

AIM: This study aimed to evaluate the efficacy and safety of OsteoKing compared to a standard active comparator (Yaobitong capsules) for managing lumbar disc herniation (LDH). METHODS: A randomized, double-blind, double-dummy, positive-controlled, multicenter trial was conducted across 17 hospitals in China. A total of 210 eligible patients with LDH were randomized in a 2:1 ratio to receive either OsteoKing (n = 140) or Yaobitong capsules (n = 70) for 4 weeks. The primary efficacy endpoint was the change in the Visual Analog Scale (VAS) score from baseline to week 4. Secondary endpoints included the Oswestry Disability Index score, the resolution rate of individual traditional Chinese medicine symptoms, and safety assessments. Missing data and repeated measures were handled using multiple imputation and a mixed-model for repeated measures. RESULTS: Baseline characteristics were well-matched between the two groups. At week 4, both groups experienced substantial improvements in pain and lumbar function. In the full analysis set (FAS), the between-group least squares mean difference (LSMD) in VAS reduction was -0.37 (95% CI: -0.77 to 0.03; p = 0.074). In the per-protocol set (PPS) analysis, the OsteoKing group achieved a significantly greater reduction in VAS scores compared to the control group (LSMD: -0.41, 95% CI: -0.82 to -0.01; p = 0.0453). Improvements in ODI scores were comparable between the groups in both the FAS and PPS analyses (p > 0.05). Additionally, the OsteoKing group demonstrated significantly higher resolution rates for low back pain and fatigue/lassitude at week 4 (p < 0.05). Both treatments were safe and well-tolerated, with comparable incidence rates of adverse events (21.43% vs. 24.29%, p = 0.6396). CONCLUSIONS: OsteoKing demonstrated comparable overall efficacy and safety to Yaobitong capsules in improving lumbar function and relieving symptoms in patients with LDH. Furthermore, OsteoKing may offer a modest, short-term analgesic advantage at the 4-week mark. OsteoKing represents a safe, effective, and viable conservative therapeutic option for LDH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xy完成签到 ,获得积分10
1秒前
1touzansi完成签到 ,获得积分10
2秒前
科研小书虫的应助被mawenyu采纳,获得10
2秒前
2秒前
GamAooL发布了新的文献求助10
2秒前
LiPengpeng完成签到,获得积分10
3秒前
tutu发布了新的文献求助30
3秒前
李嘉辉完成签到,获得积分10
4秒前
lss完成签到,获得积分10
4秒前
夏日随笔发布了新的文献求助10
5秒前
忆寒发布了新的文献求助10
6秒前
6秒前
李健的粉丝团团长的应助被Eli采纳,获得10
7秒前
Maestro_S的应助被AA采纳,获得10
8秒前
荼蘼发布了新的文献求助10
8秒前
Zz发布了新的文献求助10
8秒前
asd459完成签到,获得积分10
9秒前
晨晨完成签到,获得积分10
9秒前
9秒前
9秒前
完美焦发布了新的文献求助10
10秒前
Rea完成签到,获得积分10
10秒前
闪闪的映波完成签到,获得积分10
11秒前
12秒前
传奇3的应助被primriy采纳,获得10
12秒前
成就完成签到,获得积分10
13秒前
13秒前
深情安青的应助被猫猫大侠采纳,获得10
14秒前
14秒前
万万万完成签到,获得积分10
16秒前
tiantian完成签到,获得积分20
17秒前
18秒前
科研通AI2S的应助被BAEKHYUNLUCKY采纳,获得10
18秒前
19秒前
19秒前
LiWen发布了新的文献求助10
19秒前
19秒前
20秒前
仁仁仁发布了新的文献求助10
21秒前
荼蘼发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241